The in situ local immune response, tumour senescence and proliferation in colorectal cancer

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2207-2216

  Roxburgh, C S ^a   Richards, C H ^a   Macdonald, A I ^a   Powell, A G ^a   McGlynn, L M ^a   McMillan, D C ^a   Horgan, P G ^a   Edwards, J ^a   Shiels, P G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CDKN2A; colorectal cancer; immune cells; p16ink4a; proliferation; senescence

Indexed keywords

CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CELL INFILTRATION; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; T LYMPHOCYTE; TISSUE MICROARRAY; TUMOR GROWTH;

AGED; CELL AGING; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PARAFFIN EMBEDDING; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS;

EID: 84885909169     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.556     Document Type: Article

References (43)

1. Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A (2007) Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer 43(3): 624-631.
2. Cairney CJ, Bilsland AE, Evans TR, Roffey J, Bennett DC, Narita M, Torrance CJ, Keith WN (2012) Cancer cell senescence: A new frontier in drug development. Drug Discov Today 17(5-6): 269-276.
3. Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120(4): 513-522.
4. Campisi J, d0Adda di Fagagna (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8(9): 729-740.
5. Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130(2): 223-233.
6. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K (2004) Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol 35(10): 1189-1195.
7. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB (2010) Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol 11: 19.
8. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci US A 92(20): 9363-9367.
9. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Hertman JG, Capella G, Peinado MA (2001) K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19(2): 299-304.
10. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6): 448-454.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964.
12. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O?Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D?Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012) Cancer classification using the Immunoscore: A worldwide task force. J Transl Med 10(1): 205.
13. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, De Juan C, Sánchez-Pernaute A, Torres A, D?́az-Rubio E, Balibrea JL, Benito M, Iniesta P (2004) Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 24(2): 349-355.
14. Jass JR (1987) The pathological classification of colorectal cancer. Ann Acad Med Singapore 16(3): 469-473.
15. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48(7): 787-794.
16. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Ma?kela? J, Karttunen TJ, Ma?kinen MJ (2005) Inflammation and prognosis in colorectal cancer. Eur J Cancer 41(17): 2645-2654.
17. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE (2004) Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114(9): 1299-1307.
18. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A (2009) CD3? cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol 10(9): 877-884.
19. Lyall MS, Dundas SR, Curran S, Murray GI (2006) Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12(4): 1184-1191.
20. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL (2001a) Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48(3): 360-366.
21. Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Hu?ttmann AE,WalshMD, Pandeya N, Simms LA, Young JP, Leggett BA, Jass JR, Radford-Smith GL (2001b) Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 7(8): 2347-2356.
22. McGlynn LM, Stevenson K, Lamb K, Zino S, Brown M, Prina A, Kingsmore D, Shiels PG (2009) Cellular senescence in pretransplant renal biopsies predicts postoperative organ function. Aging Cell 8(1): 45-51.
23. Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T (2010) Aberrant p16(INK4a) methylation is a frequent event in colorectal cancers: Prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol 136(2): 323-331.
24. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6): 610-618.
25. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC, Edwards J (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 106(2): 383-388.
26. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8? T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16): 3491-3494.
27. Narita M, Lowe SW (2005) Senescence comes of age. Nat Med 11(9): 920-922.
28. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25): 2654-2666.
29. Pollheimer MJ, Kornprat P, Lindtner RA, Harbaum L, Schlemmer A, Rehak P, Langner C (2010) Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 41(12): 1749-1757.
30. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG (2011) BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res 17(11): 3590-3599.
31. Richards CH, Flegg KM, Roxburgh CS, Going JJ, Mohammed Z, Horgan PG, McMillan DC (2012a) The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 106(12): 2010-2015.
32. Richards CH, Roxburgh CS, Anderson JH, McKee RF, Foulis AK, Horgan PG, McMillan DC (2012b) Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg 99(2): 287-294.
33. Roxburgh CS, McMillan DC (2012) The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 38(5): 451-466.
34. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC (2009a) Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 45(12): 2138-2145.
35. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC (2009b) Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 249(5): 788-793.
36. Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151(6): 1185-1199.
37. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S (2011) Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer 128(5): 1080-1094.
38. Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim Biophys Acta 1775(1): 5-20.
39. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ (2009) Intraepithelial effector (CD3?)/regulatory (FoxP3?) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137(4): 1270-1279.
40. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11(13): 4835-4842.
41. Wassermann S,Scheel SK,Hiendlmeyer E,Palmqvist R,Horst D,Hlubek F,Haynl A Kriegl L, Reu S, Merkel S, Brabletz T, Kirchner T, Jung A (2009) p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors. Gastroenterology 136(1): 196-205 e2.
42. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128): 656-660.
43. Zhao P, Hu YC, Talbot IC (2003) Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9(10): 2202-2206.